Kenji Tamura

ORCID

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 25

Top Venues

Cancer science

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of gynecologic oncology

American journal of hematology

National Cancer Center Hospital Tokyo (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

National Cancer Center Hospital Tokyo

Japan

PHD :: Breast and Medical Oncology

Publications

Yutaka Yamamoto, Hiroji Iwata, Naruto Taira, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS). Cancer science 113 (9) (2022)
Satoru Iwasa, Takafumi Koyama, Makoto Nishino, Shunsuke Kondo, Kazuki Sudo, Kan Yonemori, Tatsuya Yoshida, Kenji Tamura, Toshio Shimizu, Yutaka Fujiwara, Shigehisa Kitano, Akihiko Shimomura, Jun Sato, Fumiharu Yokoyama, Hiroyuki Iida, Maki Kondo, Noboru Yamamoto
First-in-human study of ONO-4578, an antagonist of prostaglandin E 2 receptor 4, alone and with nivolumab in solid tumors. Cancer science (2022)
Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, Noboru Yamamoto
First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (14) (2021)
Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Yusuke Ogitani, Tadaaki Nishikawa, Mayu Ohuchi, Takashi Teishikata, Takahiro Jikoh, Yasushi Yatabe, Kan Yonemori, Kenji Tamura, Kosei Hasegawa, Akinobu Hamada
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (14) (2021)
Shunsuke Kondo, Toshio Shimizu, Takafumi Koyama, Jun Sato, Satoru Iwasa, Kan Yonemori, Yutaka Fujiwara, Akihiko Shimomura, Shigehisa Kitano, Kenji Tamura, Noboru Yamamoto
First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer science 112 (4) (2021)
Lillian M Smyth, Kenji Tamura, Mafalda Oliveira, Eva Ciruelos Gil, Ingrid A Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J Ambrose, Jack Ashton, Alan Barnicle, Des D Cashell, Claire Corcoran, Elza C de Bruin, Andrew Foxley, Joana Hauser, Justin P O Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S Taylor, Sarat Chandarlapaty, José Baselga, David M Hyman
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (15) (2020)
Takuji Seo, Emi Noguchi, Masayuki Yoshida, Taisuke Mori, Maki Tanioka, Kazuki Sudo, Akihiko Shimomura, Kan Yonemori, Yasuhiro Fujiwara, Kenji Tamura
Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case reports in oncological medicine 2020 (2020)
Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T Li
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer discovery 10 (5) (2020)
Kenji Tamura, Kosei Hasegawa, Noriyuki Katsumata, Koji Matsumoto, Hirofumi Mukai, Shunji Takahashi, Hiroyuki Nomura, Hironobu Minami
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial. Cancer science 110 (9) (2019)
Seiko Bun, Mayu Yunokawa, Takahiro Ebata, Mayumi Kobayashi Kato, Tatsunori Shimoi, Tomoyasu Kato, Kenji Tamura
Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study. International journal of clinical oncology 24 (9) (2019)
Kan Yonemori, Makoto Kodaira, Taroh Satoh, Toshihiro Kudo, Shunji Takahashi, Kenji Nakano, Yuichi Ando, Tomoya Shimokata, Joji Mori, Koichi Inoue, Gerard J Oakley, Sachi Sakaguchi, Kenji Tamura
Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma. Cancer science 109 (12) (2019)
Keiko Goto, Yutaka Fujiwara, Takeshi Isobe, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Yukari Tsubata, Takamasa Hotta, Kenji Tamura, Noboru Yamamoto, Hironobu Minami
Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function. Cancer science 110 (6) (2019)
Masamichi Takahashi, Shunichiro Miki, Kenji Fujimoto, Kohei Fukuoka, Yuko Matsushita, Yoshiko Maida, Mami Yasukawa, Mitsuhiro Hayashi, Raku Shinkyo, Kiyomi Kikuchi, Akitake Mukasa, Ryo Nishikawa, Kenji Tamura, Yoshitaka Narita, Akinobu Hamada, Kenkichi Masutomi, Koichi Ichimura
Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer science 110 (7) (2019)
Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo, Mamoru Kato, Yutaka Fujiwara, Akihiko Shimomura, Takafumi Koyama, Hiroki Kakishima, Mayuko Kitami, Hiromichi Matsushita, Eisaku Furukawa, Daichi Narushima, Momoko Nagai, Hirokazu Taniguchi, Noriko Motoi, Shigeki Sekine, Akiko Miyagi Maeshima, Taisuke Mori, Reiko Watanabe, Masayuki Yoshida, Akihiko Yoshida, Hiroshi Yoshida, Kaishi Satomi, Aoi Sukeda, Taiki Hashimoto, Toshio Shimizu, Satoru Iwasa, Kan Yonemori, Ken Kato, Chigusa Morizane, Chitose Ogawa, Noriko Tanabe, Kokichi Sugano, Nobuyoshi Hiraoka, Kenji Tamura, Teruhiko Yoshida, Yasuhiro Fujiwara, Atsushi Ochiai, Noboru Yamamoto, Takashi Kohno
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer science 110 (4) (2019)
Kenta Takahashi, Mayu Yunokawa, Shinsuke Sasada, Yae Takehara, Naoyuki Miyasaka, Tomoyasu Kato, Kenji Tamura
A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma. Journal of gynecologic oncology 30 (1) (2018)
Shinsuke Sasada, Mayu Yunokawa, Yae Takehara, Mitsuya Ishikawa, Shunichi Ikeda, Tomoyasu Kato, Kenji Tamura
Baseline risk of recurrence in stage I-II endometrial carcinoma. Journal of gynecologic oncology 29 (1) (2018)
Kenji Tamura, Makoto Kodaira, Chikako Shimizu, Kan Yonemori, Mayu Yunokawa, Akihiko Shimomura, Takayuki Kobayashi, Kenji Nakano, Junichi Tomomatsu, Yoshinori Ito, Jun Tanaka, Hiroshi Kuriki, Zhaodi Gu, Shunji Takahashi
Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. Cancer science 109 (5) (2018)
Chihiro Udagawa, Hiromi Nakamura, Hiroshi Ohnishi, Kenji Tamura, Tatsunori Shimoi, Masayuki Yoshida, Teruhiko Yoshida, Yasushi Totoki, Tatsuhiro Shibata, Hitoshi Zembutsu
Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity. Cancer science 109 (2) (2018)
Tatsunori Shimoi, Akinobu Hamada, Marifu Yamagishi, Mitsuharu Hirai, Masayuki Yoshida, Tadaaki Nishikawa, Kazuki Sudo, Akihiko Shimomura, Emi Noguchi, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Takayuki Kinoshita, Takahiro Fukuda, Yasuhiro Fujiwara, Kenji Tamura
PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. Cancer science 109 (8) (2018)
Satoru Iwasa, Noboru Yamamoto, Kohei Shitara, Kenji Tamura, Nobuaki Matsubara, Masaomi Tajimi, Aimee B Lin, Hiroya Asou, Zhihong Cai, Koichi Inoue, Yuko Shibasaki, Kanako Saito, Hiroki Takai, Toshihiko Doi
Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors. Cancer science 109 (10) (2018)
Carlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T Beck, William Jeffrey Edenfield, Yuan-Kai Shi, Matthew Taylor, Kenji Tamura, Brian A Van Tine, Shang-Ju Wu, Jolanda Paolini, Paulina Selaru, Tae Min Kim
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. American journal of hematology 93 (5) (2018)
Tadaaki Nishikawa, Koji Matsumoto, Kenji Tamura, Hiroyuki Yoshida, Yuichi Imai, Aki Miyasaka, Takuma Onoe, Satoshi Yamaguchi, Chikako Shimizu, Kan Yonemori, Tatsunori Shimoi, Mayu Yunokawa, Hao Xiong, Silpa Nuthalapati, Hideyuki Hashiba, Tsukasa Kiriyama, Terri Leahy, Philip Komarnitsky, Keiichi Fujiwara
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. Cancer science 108 (9) (2017)
Akihiro Hirakawa, Kan Yonemori, Fumie Kinoshita, Yumiko Kobayashi, Hitomi S Okuma, Asuka Kawachi, Kenji Tamura, Yasuhiro Fujiwara, Larry Rubinstein, Pamela Jo Harris, Naoko Takebe
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer science 109 (1) (2017)
Kenji Tamura, Kenichi Inoue, Norikazu Masuda, Shintaro Takao, Masahiro Kashiwaba, Yutaka Tokuda, Hiroji Iwata, Naohito Yamamoto, Kenjiro Aogi, Toshiaki Saeki, Takahiro Nakayama, Nobuaki Sato, Tatsuya Toyama, Takanori Ishida, Hitoshi Arioka, Mitsue Saito, Shinji Ohno, Hideko Yamauchi, Kimito Yamada, Junichiro Watanabe, Hiroshi Ishiguro, Yasuhiro Fujiwara
Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer science 108 (5) (2017)
Yuko Tanabe, Hitoshi Tsuda, Masayuki Yoshida, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Seiichiro Yamamoto, Takayuki Kinoshita, Yasuhiro Fujiwara, Kenji Tamura
Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. Cancer science 108 (7) (2017)

Kenji Tamura.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Kenji Tamura